Tumor specific glycoproteins and method for detecting tumorigenic cancers
US4146603A · kind A · utility
21Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 1977 |
| Grant date | Mar 27, 1979 |
| Priority date | — |
| Expiry date | Feb 18, 1997 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/83
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A new class of glycoproteins has been found to be produced by human cancer cells and is not produced by normal cells and said glycoprotein is present in the sera of cancer patients. This tumor specific glycoprotein can be characterized by its isoelectric point of from about 4.2 to 4.6 and by the perchloric acid soluble fraction thereof having a sialic acid content of above about 0.065 mg/ml of initial serum sample. The presence of a tumorigenic cancer in a patient can be determined by detecting the presence of the tumor specific glycoprotein in the blood sera of a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.